A novel cuproptosis pattern and tumor immune microenvironment characterization in urothelial carcinoma of the bladder

被引:2
作者
Feng, Huan [1 ,2 ,3 ,4 ]
Deng, Zhiyao [1 ,2 ,3 ]
Huang, Yibao [5 ]
Liu, Zhuo [1 ,2 ]
Ruan, Yajun [1 ,2 ]
Wang, Tao [1 ,2 ,3 ]
Liu, Jihong [1 ,2 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Urol, Wuhan, Hubei, Peoples R China
[2] Huazhong Univ Sci & Technol, Tongji Hosp, Inst Urol, Tongji Med Coll, Wuhan, Hubei, Peoples R China
[3] Shenzhen Huazhong Univ Sci & Technol, Res Inst, Shenzhen, Guangdong, Peoples R China
[4] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Thorac Surg, Wuhan, Hubei, Peoples R China
[5] Guangxi Med Univ, Affiliated Hosp 2, Dept Gynaecol, Nanning, Guangxi, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
基金
中国国家自然科学基金;
关键词
cuproptosis; tumor immune microenvironment; urothelial carcinoma of the bladder; immunotherapy; prognosis; SERUM COPPER; CELL-DEATH; CANCER; FERROPTOSIS;
D O I
10.3389/fimmu.2023.1219209
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Urothelial carcinoma of the bladder (UCB) is the most prevalent malignant tumor of the urinary system worldwide, which has a significant recurrence rate despite multiple treatment options available. As a unique and novel copper-dependent programmed cell death mechanism, the comprehensive impact of cuproptosis on the tumor immune microenvironment, clinicopathological characteristics and the prognosis of patients remains largely unclear.Methods: A total of 568 UCB samples were thoroughly examined for cuproptosis patterns using data downloaded from TCGA and GEO, based on 10 cuproptosis-related genes reported previously. Then, the univariate COX regression analysis was performed on the genes that differed across the various patterns. To measure individual cuproptosis pattern, a cuproptosis score system was constructed using a principal component analysis algorithm. To validate the scoring system, immunohistochemical staining was performed on tumor tissues with different pathological grades, and experiments in vitro were conducted about the differentially expressed genes related to prognosis. Finally, the capacity of scoring system to predict the response to immunotherapy was verified by using data from IMvigor 210 cohort.Results: Four unique cuproptosis clusters and two gene clusters were finally found by the investigation. The clinical features and prognosis of patients, as well as the mRNA transcriptome, pathway enrichment, and immune cell infiltration in TME, varied dramatically between various cuproptosis clusters and gene clusters. To identify individual cuproptosis patterns in UCB patients, we also established a cuproptosis scoring system. After validation with multiple methods, it was indicated that the score system could predict the prognosis of UCB patients and was significantly connected to clinical features such TNM category, tumor grade, molecular type and ultimate survival status. The clinical outcomes of UCB patients were predicted effectively according to the tumor mutation burden in conjunction with the scoring system. Furthermore, we found that the cuproptosis score had a significant correlation with the response to immunotherapy and the sensitivity to chemotherapy.Conclusion: This study revealed the potential impact of cuproptosis on the UCB tumor immune microenvironment and clinical pathological characteristics. The cuproptosis score system could effectively predict the prognosis of patients and the response to chemotherapy and immunotherapy.
引用
收藏
页数:19
相关论文
共 62 条
  • [1] Aran D, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10707
  • [2] Cysteine depletion induces pancreatic tumor ferroptosis in mice
    Badgley, Michael A.
    Kremer, Daniel M.
    Maurer, H. Carlo
    DelGiorno, Kathleen E.
    Lee, Ho-Joon
    Purohit, Vinee
    Sagalovskiy, Irina R.
    Ma, Alice
    Kapilian, Jonathan
    Firl, Christina E. M.
    Decker, Amanda R.
    Sastra, Steve A.
    Palermo, Carmine F.
    Andrade, Leonardo R.
    Sajjakulnukit, Peter
    Zhang, Li
    Tolstyka, Zachary P.
    Hirschhorn, Tal
    Lamb, Candice
    Liu, Tong
    Gu, Wei
    Seeley, E. Scott
    Stone, Everett
    Georgiou, George
    Manor, Uri
    Iuga, Alina
    Wahl, Geoffrey M.
    Stockwell, Brent R.
    Lyssiotis, Costas A.
    Olive, Kenneth P.
    [J]. SCIENCE, 2020, 368 (6486) : 85 - +
  • [3] Understanding the tumor immune microenvironment (TIME) for effective therapy
    Binnewies, Mikhail
    Roberts, Edward W.
    Kersten, Kelly
    Chan, Vincent
    Fearon, Douglas F.
    Merad, Miriam
    Coussens, Lisa M.
    Gabrilovich, Dmitry I.
    Ostrand-Rosenberg, Suzanne
    Hedrick, Catherine C.
    Vonderheide, Robert H.
    Pittet, Mikael J.
    Jain, Rakesh K.
    Zou, Weiping
    Howcroft, T. Kevin
    Woodhouse, Elisa C.
    Weinberg, Robert A.
    Krummel, Matthew F.
    [J]. NATURE MEDICINE, 2018, 24 (05) : 541 - 550
  • [4] Long non-coding RNA in bladder cancer
    Cao, Yuepeng
    Tian, Tian
    Li, Weijian
    Xue, Hanzi
    Zhan, Chuanfei
    Wu, Xuhong
    Wang, Chao
    Wu, Xiaoli
    Wu, Wanke
    Zheng, Shuyun
    Xie, Kaipeng
    [J]. CLINICA CHIMICA ACTA, 2020, 503 : 113 - 121
  • [5] The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma
    Cathomas, Richard
    Lorch, Anja
    Bruins, Harman M.
    Comperat, Eva M.
    Cowan, Nigel C.
    Efstathiou, Jason A.
    Fietkau, Rainer
    Gakis, Georgios
    Hernandez, Virginia
    Espinos, Estefania Linares
    Neuzillet, Yann
    Ribal, Maria J.
    Rouanne, Matthieu
    Thalmann, George N.
    van der Heijden, Antoine G.
    Veskimae, Erik
    Witjes, J. Alfred
    Milowsky, Matthew I.
    [J]. EUROPEAN UROLOGY, 2022, 81 (01) : 95 - 103
  • [6] Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
    Chan, T. A.
    Yarchoan, M.
    Jaffee, E.
    Swanton, C.
    Quezada, S. A.
    Stenzinger, A.
    Peters, S.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 (01) : 44 - 56
  • [7] Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade
    Charoentong, Pornpimol
    Finotello, Francesca
    Angelova, Mihaela
    Mayer, Clemens
    Efremova, Mirjana
    Rieder, Dietmar
    Hackl, Hubert
    Trajanoski, Zlatko
    [J]. CELL REPORTS, 2017, 18 (01): : 248 - 262
  • [8] Elements of cancer immunity and the cancer-immune set point
    Chen, Daniel S.
    Mellman, Ira
    [J]. NATURE, 2017, 541 (7637) : 321 - 330
  • [9] Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine
    Conway, Jake R.
    Kofman, Eric
    Mo, Shirley S.
    Elmarakeby, Haitham
    Van Allen, Eliezer
    [J]. GENOME MEDICINE, 2018, 10
  • [10] TGFβ biology in cancer progression and immunotherapy
    Derynck, Rik
    Turley, Shannon J.
    Akhurst, Rosemary J.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2021, 18 (01) : 9 - 34